Related Experiment Video

Updated: Jun 19, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Hepatitis C comorbidities affecting the course and response to therapy

Abdel-Rahman El-Zayadi

    World Journal of Gastroenterology
    |October 28, 2009
    PubMed

    Insights

    Comorbidities significantly impact chronic hepatitis C (CHC) outcomes and antiviral treatment response. Addressing these conditions is crucial for improving patient prognosis and treatment success in CHC patients.

    Area of Science:

    • Hepatology
    • Infectious Diseases
    • Internal Medicine

    Background:

    • Chronic hepatitis C (CHC) infection outcomes are significantly influenced by comorbidities.
    • These co-existing conditions can negatively affect liver disease progression and treatment efficacy.

    Purpose of the Study:

    • To review the impact of various comorbidities on the course and treatment response of chronic hepatitis C.
    • To identify key comorbidities affecting sustained virological response to antiviral therapies.

    Main Methods:

    • Literature review of studies examining comorbidities in chronic hepatitis C.
    • Analysis of how different comorbidities affect disease progression and response to PEGylated interferon and ribavirin.

    Main Results:

    • Comorbidities negatively impact CHC course and reduce sustained virological response rates.
    • Key comorbidities include hepatitis B coinfection, metabolic syndrome, intestinal bacterial overgrowth, schistosomiasis, iron overload, alcohol abuse, smoking, depression, anemia, cardiovascular disease, and renal failure.
    • These conditions can decrease patient adherence and lead to suboptimal dosing of antiviral therapy.

    Conclusions:

    • Comorbidities represent a significant challenge in managing chronic hepatitis C.
    • Effective management of comorbidities is essential for optimizing treatment outcomes and improving the prognosis for patients with CHC.

    More Related Videos

    An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis06:38

    An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

    Published on: September 12, 2019

    Related Concept Videos

    Hepatitis01:25

    Hepatitis

    Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
    Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

    Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

    Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
    Cirrhosis II: Pathophysiology01:24

    Cirrhosis II: Pathophysiology

    Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
    Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

    Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

    Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
    Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

    Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

    In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
    Cirrhosis I: Introduction01:23

    Cirrhosis I: Introduction

    Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...